Trials / Completed
CompletedNCT04566770
A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 480 (actual)
- Sponsor
- CanSino Biologics Inc. · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, double-blind, placebo -controlled IIb clinical trial, in order to evaluate the safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in people 6 years old and above and .
Detailed description
This is a phase IIb clinical trial to evaluate safety and immuogenicity of Ad5-nCoV developed by Cansino and Beijing Institute of Biotechnology in health people aged 6 years old and above. The study will be double-blind, placebo-controlled trial with participants randomly allocated 2:1 to placebo and experimental vaccine . The immunization schedule is two doses intramuscular injections (deltoid).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | Intramuscular other name:Ad5-nCoV |
| BIOLOGICAL | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo | Intramuscular other name:Ad5-nCoV |
Timeline
- Start date
- 2020-09-24
- Primary completion
- 2021-09-21
- Completion
- 2022-01-19
- First posted
- 2020-09-28
- Last updated
- 2022-10-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04566770. Inclusion in this directory is not an endorsement.